News
Sanofi axes diabetes R&D, focuses on 'transformative' therap...
Take a look at Sanofi’s balance sheet and it’s obvious which way the wind is blowing – sales in its once mighty diabetes franchise are sliding, while newer medicines such as its eczema and
